Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY 2025 Earnings Guidance

Ligand Pharmaceuticals (NASDAQ:LGND) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 6.000-6.250 for the period, compared to the consensus EPS estimate of 6.140. The company issued revenue guidance of $180.0 million-$200.0 million, compared to the consensus revenue estimate of $188.8 million.

Analyst Upgrades and Downgrades

LGND has been the topic of several research reports. Royal Bank of Canada upped their price target on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Benchmark restated a “buy” rating and set a $135.00 target price on shares of Ligand Pharmaceuticals in a research report on Monday, December 23rd. Oppenheimer boosted their price target on shares of Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Barclays lifted their target price on shares of Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Finally, HC Wainwright reiterated a “buy” rating on shares of Ligand Pharmaceuticals in a report on Wednesday, December 11th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $147.00.

Ligand Pharmaceuticals Trading Up 4.0 %

NASDAQ:LGND traded up $4.61 on Friday, hitting $120.28. The company had a trading volume of 65,778 shares, compared to its average volume of 90,501. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of 47.92 and a beta of 1.04. Ligand Pharmaceuticals has a 52 week low of $67.72 and a 52 week high of $129.90. The firm has a 50 day moving average of $114.03 and a two-hundred day moving average of $111.01.

Insiders Place Their Bets

In related news, CFO Octavio Espinoza sold 2,104 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $116.37, for a total transaction of $244,842.48. Following the completion of the sale, the chief financial officer now directly owns 20,647 shares in the company, valued at $2,402,691.39. This represents a 9.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.90% of the stock is currently owned by insiders.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.